Marinus Pharmaceuticals (NASDAQ:MRNS) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $13.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Truist Financial reissued a buy rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. StockNews.com raised Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Monday, September 9th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $10.25.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $1.55 on Monday. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The company has a quick ratio of 2.15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68. The stock’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $3.00. The firm has a market capitalization of $85.15 million, a PE ratio of -0.59 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter in the previous year, the business posted ($0.61) earnings per share. On average, analysts anticipate that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the second quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth $64,000. AQR Capital Management LLC grew its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares during the period. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $206,000. Finally, XTX Topco Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter worth $232,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.